Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Fulgent Genetics, Inc.NASDAQ: FLGT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $24.83M (cash outflow) rose 108.6% year over year, ahead of the +78.1% change in trailing-twelve-month net income. Sequentially, it rose 5.0% from the prior quarter.
Context
- Net income amounted to 19.1% of revenue in FY2025, up 3.6 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$52.32M (-15.1%) for the fiscal year ending Dec 2026, a slowdown from the +40.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$24.83M+5.0% QoQ
- Last fiscal yearDec 2025
- -$61.63M+40.6% YoY
- LTMMar 2026
- -$74.56M+78.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +108.6% | -33.9% | -142.6 pp |
| 1 year | +40.6% | -15.1% | -55.8 pp |
| 3-year CAGR | — | -21.2% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (61.63M) USD
- Year-over-year change
- -40.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (61.63M) | -40.6% |
| FY2024 | 2024-12-31 | (43.82M) | +75.0% |
| FY2023 | 2023-12-31 | (175.24M) | -223.5% |
| FY2022 | 2022-12-31 | 141.92M | -72.0% |
| FY2021 | 2021-12-31 | 506.24M | — |
Net Income vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 net income of $74.56M is the 6th largest of the 8 companies compared; the peer median is $106.36M.
- Its year-over-year change of +78.1% is the 2nd highest of 7, against a peer median of -5.2%.
- Net income amounts to 23.3% of revenue for FLGT, versus a peer median of 23.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $485.07M | +21.6% | -14.0% | 37.9% | |
| LTM Mar 2026 | $399.9M | +294.4% | +48.4% | 48.2% | |
| LTM Jun 2026 | $192.35M | -24.0% | -27.6% | 7.1% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $106.36M | -7664.5% | -66.3% | 23.4% |
| LTM Mar 2026 | $95.55M | +13.7% | -10.5% | 148.1% | |
| LTM Mar 2026 | $74.56M | +78.1% | — | 23.3% | |
| LTM Jun 2026 | $51.88M | -50.1% | -9.2% | 6.8% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $37.71M | — | — | 9.5% |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | $106.36M | -5.2% | -12.2% | 23.4% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 506.24M | 141.92M | (175.24M) | (43.82M) | (61.63M) |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| Deferred Income Tax | (7.84M) | 831K | 7.61M | (5.15M) | (1.21M) |
| Stock-Based Compensation | 15.88M | 32.64M | 42.92M | 44.48M | 39.58M |
| Change in Working Capital | (2.68M) | 2.01M | 2.84M | (7.24M) | (117.63M) |
| Accounts Receivables | 42.3M | 68.64M | 2.39M | (16.3M) | (23.25M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (12.21M) | (25.34M) | (6.9M) | 3.07M | 550K |
| Other Working Capital | (32.77M) | (41.29M) | 7.35M | 6M | (94.93M) |
| Other Non-Cash Items | 15.97M | 43.46M | 122.73M | 7.86M | 15.14M |
| Operating Cash Flow | 538.58M | 253.52M | 27M | 21.06M | (101.64M) |
| Capital Expenditures | (23.84M) | (18.78M) | (22.21M) | (40.32M) | (22.57M) |
| Acquisitions (Net) | (61.87M) | (182.68M) | (399K) | 0 | 3.78M |
| Purchases of Investments | (730.49M) | (432.98M) | (491.91M) | (472.42M) | (80.84M) |
| Sales of Investments | 269.59M | 372.71M | 552.64M | 454.07M | 211.01M |
| Other Investing Activities | 31K | 412K | 775K | 313K | 5K |
| Investing Cash Flow | (546.55M) | (261.31M) | 38.9M | (58.35M) | 111.37M |
| Debt Repayment | (11K) | (1.07M) | (20M) | (1.77M) | (870K) |
| Common Stock Issued | 89.48M | 0 | 0 | 0 | 1K |
| Common Stock Repurchased | (4.16M) | (76.11M) | (27.79M) | (3.12M) | (13.92M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 96K | 31K | 3K | 51K | 0 |
| Financing Cash Flow | 85.41M | (77.14M) | (47.79M) | (4.85M) | (14.79M) |
| Effect of Forex Changes | 34K | (453K) | (149K) | (55K) | 105K |
| Net Change in Cash | 77.47M | (85.39M) | 17.97M | (42.19M) | (4.95M) |
| Free Cash Flow | 514.73M | 234.75M | 4.8M | (19.26M) | (124.21M) |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.